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Abstract
Background: Oncolytic virotherapy for cancer treatment utilizes viruses for selective infection and death of cancer
cells without any adverse effect on normal cells. We previously reported that the human respiratory syncytial virus
(RSV) is a novel oncolytic virus against androgen-independent PC-3 human prostate cancer cells. The present study
extends the result to androgen-dependent prostate cancer, and explores the underlying mechanism that triggers
RSV-induced oncolysis of prostate cancer cells.
Methods: The oncolytic effect of RSV on androgen-sensitive LNCaP human prostate cancer cells and on androgen-
independent RM1 murine prostate cancer cells was studied in vitro in culture and in vivo in a xenograft or allograft
tumor model. In vitro, cell viability, infectivity and apoptosis were monitored by MTT assay, viral plaque assay and
annexin V staining, respectively. In vivo studies involved virus administration to prostate tumors grown in immune
compromised nude mice and in syngeneic immune competent C57BL/6J mice. Anti-tumorogenic oncolytic activity
was monitored by measuring tumor volume, imaging bioluminescent tumors in live animals and performing
histopathological analysis and TUNEL assay with tumors
Results: We show that RSV imposes a potent oncolytic effect on LNCaP prostate cancer cells. RSV infectivity was
markedly higher in LNCaP cells compared to the non-tumorigenic RWPE-1 human prostate cells. The enhanced
viral burden led to LNCaP cell apoptosis and growth inhibition of LNCaP xenograft tumors in nude mice. A
functional host immune response did not interfere with RSV-induced oncolysis, since growth of xenograft tumors
in syngeneic C57BL/6J mice from murine RM1 cells was inhibited upon RSV administration. LNCaP cells failed to
activate the type-I interferon (IFNa/b)-induced transcription factor STAT-1, which is required for antiviral gene
expression, although these cells could produce IFN in response to RSV infection. The essential role of IFN in
restricting infection was further borne out by our finding that neutralizing IFN activity resulted in enhanced RSV
infection in non-tumorigenic RWPE-1 prostate cells.
Conclusions: We demonstrated that RSV is potentially a useful therapeutic tool in the treatment of androgen-
sensitive and androgen-independent prostate cancer. Moreover, impaired IFN-mediated antiviral response is the
likely cause of higher viral burden and resulting oncolysis of androgen-sensitive prostate cancer cells.
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Oncolytic virotherapy, which takes advantage of selective
viral infection and apoptosis in cancer cells due to
robust viral replication, is emerging as an important
alternative to conventional cancer treatment modalities
[1-4]. Evidence indicates that concurrent use of a reper-
toire of different oncolytic viruses (with different modes
of action) may produce more efficacious therapeutic
response. Human respiratory syncytial virus (RSV) is a
respiratory tract-specific enveloped non-segmented
negative sense single stranded RNA (NNS) virus of the
paramyxovirus family [5,6]. We have recently identified
RSV as an oncolytic virus byd e m o n s t r a t i n gt h a tR S V
can cause apoptosis of PC-3 human prostate cancer
cells in culture and in a xenograft tumor environment
as a consequence of excessive viral replication in PC-3
cells that led to apoptotic cell death [7]. Specificity of
the virus-induced oncolysis of cancer cells was evident
from the lack of significant viral burden and apoptosis
of non-tumorigenic human prostate epithelial cells, such
as RWPE-1.
Metastatic prostate cancer is a leading cause of cancer
deaths in men in the United States. The steroid hor-
mone androgen is a potent mitogen for normal and can-
cerous prostate epithelial cells. The cognate androgen
receptor (AR) mediates nuclear responses to androgen
signaling [8,9]. Although initially androgen-sensitive,
metastatic prostate cancer evolves to a state of androgen
independence for growth and proliferation, despite con-
tinued expression of AR at all stages of the disease. AR
was shown to activate the transcriptional program of a
distinct set of gene networks, including many genes
involved in cell cycle regulation, during progression of
the cancer cells to androgen independence [9]. As noted
above, RSV can induce oncolysis of androgen-indepen-
dent PC-3 prostate cancer cells and RSV caused regres-
sion of PC-3 cell derived xenograft tumors in immune-
deficient nude mice [7]. Extending this study, we exam-
ined susceptibility of the androgen-sensitive LNCaP
human prostate cancer cells and LNCaP xenograft
tumors to RSV-induced oncolysis, and the impact of
host immune-competence on the oncolytic activity of
RSV. Innate immunity is the first line of antiviral
defense for restricting virus growth and spread. Since
both NF-B and type-I interferon (IFNa/b)-mediated
JAK/STAT signaling [10] is required for innate antiviral
response; we also examined the activation status of NF-
B and IFN-induced JAK-STAT pathways in RSV-
infected prostate cancer cells.
Herein we report that RSV is potently oncolytic
against androgen-sensitive LNCaP human prostate can-
cer cells in vitro and in vivo, and aberrant IFN-regulated
signaling accounts for LNCaP cell susceptibility to RSV.
While RWPE-1 non-tumorigenic prostate cells were
protected against RSV infection by activation of JAK-
STAT and NF-B signaling, a lack of sustained NF-B
activation was associated with the susceptibility of PC-3
androgen-independent prostate cancer cells to RSV-
induced oncolysis, although IFN-mediated signaling was
functional in these cells.
Methods
Virus, Cells, Culture Conditions, Chemicals
RSV (A2 strain, ATCC, Manassas, VA) was propagated
in CV-1 cells. Viral titer was monitored by plaque assay
[7]. LNCaP, PC-3 and RWPE-1 (source: ATCC) were
cultured as per the supplier’s instructions. RM1 murine
prostate cancer cells were cultured in DMEM [11,12].
RM1 cells (a gift from Dr. Timothy Thompson, Baylor
College of Medicine, TX) originated from stable expres-
sion of Ha-Ras and c-Myc oncogenes in mouse prostate
epithelial cells [11,12]. RM1 cells express androgen
receptor but they are androgen-independent. Interferon-
a (IFN-a) and Tumor necrosis factor-a (TNF-a)w e r e
purchased from R&D Systems (Minneapolis, MN).
RSV infection, interferon (IFN) treatment, ELISA for IFN-b,
IFN-g and IL-10
RSV (1 MOI) was added to cells for adsorption at 37°C
for 1.5 h. After washing, infection continued for addi-
tional 0 h-48 h. At various time points post-infection,
virus yields in culture supernatants were assayed by pla-
que assay of the monolayer of CV-1 cells (African green
monkey kidney cells) covered with a nutrient medium
in methyl-cellulose [7]. Crystal violet staining of living
cells allowed clear visualization of the plaques. Cell mor-
phology was visualized microscopically. In some experi-
ments, cells were pre-treated with 1000 units/ml IFN-a
for 16 h, followed by infection with RSV for 24 h in the
presence of IFN. Medium supernatants were used to
measure viral titer (plaque assay).
Medium supernatants from RSV-infected cells at 16 h
post-infection were analyzed for IFN-b levels using a
human IFN-b specific ELISA kit (PBL Interferon Source,
NJ). In some experiments, spleen homogenate and
tumor homogenate obtainedf r o mm i c ew e r ea n a l y z e d
for IFN-g and IL-10 levels using FACS based cytokine
bead array (BD Biosciences, San Jose, CA).
Apoptosis, cell viability
Cells infected with RSV for 24 h-36 h, were examined
for apoptosis by annexinV labeling, using annexin V/
propidium iodide apoptosis detection kit (BioVision,
CA) and for cell viability using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay [13].
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Page 2 of 18Xenograft prostate tumors in nude mice and allograft
tumors in syngeneic C57BL/6J mice
4 - 6 - w e e k - o l da t h y m i cn u d em a l em i c e( H a r l a nL a b o r a -
tories Inc.) were injected subcutaneously with 3 × 10
6
LNCaP cells at a site below the ear [7]. When tumors
reached palpable size (sizes ranging from 100-300 mm
3
for individual mice), RSV (at 1 × 10
6 pfu per animal) or
Opti-MEM (Medium, carrier control) was injected
repeatedly into the tumor mass (intratumoral adminis-
tration) at 2-day intervals over a two-week period.
Tumor volumes were measured by a caliper (4/3 × 3.14
×r 1
2 ×r 2 with r1 <r 2) and normalized to the tumor
volume for the corresponding mouse at day-1 when the
first injection was administered. Tumor samples from
euthanized mice were excised and processed for histol-
ogy and for TUNEL assay to evaluate apoptosis.
For imaging of subcutaneous xenograft tumors, which
were generated using luciferase-expressing LNCaP-Luc-
2 cells, palpable tumors were injected with RSV (1 × 10
6
pfu per animal via the intratumoral (I.T.) route) or Opti-
MEM (Medium, carrier control). At various days post-
infection, luciferin was injected and real-time tumor bio-
luminescence (reflecting tumor growth) was monitored
in live animals using the Xenogen IVIS imaging system
(Caliper Life Sciences, Hopkinton, MA).
To analyze prostate tumors in syngeneic C57BL/6J
mice, 4-6 week-old mice were injected subcutaneously
with RM1 murine prostate cancer cells (1 × 10
6 cells) in
the right dorsal flank. Tumors (tumor volumes ranging
from 56-164 mm
3 for individual mice) were injected
intra-tumorally with either RSV (at 1 × 10
6 pfu, each
animal) or Opti-MEM. The tumor volume for each ani-
mal was normalized to the corresponding volume
recorded just prior to the first injection.
Housing and all procedures involving animals were
performed according to protocols approved by the Insti-
tutional Committee for Animal Care and Use of the
University of Texas Health Science Center San Antonio.
Electrophoretic gel mobility shift (EMSA)
RSV-infected (0-24 h) or mock-infected cells were pro-
cessed for nuclear fraction enriched total cell extracts
[14]. In some cases, cells were treated with IFN-a (1000
units/ml, 4 h) or TNF-a (30 ng/m, 2 h). Nuclear
extracts were incubated with
32P-labeled oligonucleotide
duplex for cis-elements of NF-B (IL6 promoter) or
STAT-1 (hSIE/m67, synthetic c-sis-inducible element).
Protein-DNA complex was analyzed as before [15].
NFBe l e m e n t :5 ’-GGGAATTCCCCATCTACGCTA;
STAT-1 element: 5’-GTCGACA-TTTCCCGTAAATC.
Histopathology and TUNEL
Part of tumor tissues (excised immediately after eutha-
nasia) was fixed in 10% neutral buffered formalin,
embedded in paraffin, sectioned at 5 micron and ana-
lyzed for histology after staining with hematoxylin and
eosin. TUNEL staining in situ was performed using
DeadEnd Colorimetric kit (Promega, WI). For each
tumor sample, pathologic changes were graded by a
blinded board certified veterinary pathologist (GBH).
Grading criteria were based on invasion of adjacent nor-
mal tissue, necrosis, mitotic figures per 20X high power
field, edema, congestion, compression of the surround-
ing tissue, mineralization, inflammation (granulocytes,
lymphocytes, mixed), hemorrhage, neovascularization
and hemosiderin deposition.
Statistics
Differential tumor growth was determined utilizing
STATA Analysis and Statistical Software (College Sta-
tion, Texas, USA). Results are mean values ± Standard
Error (SE) of the mean. For each mouse, the tumor
volume at every time point was normalized to its tumor
volume at the start of RSV (or Medium) injection,
which was set as 100%. Significance of the difference
between Medium- and RSV-injected tumor growth tra-
jectories was evaluated using linear mixed model that
incorporated a random intercept for each mouse and
used normalized mean tumor volume measurements as
the dependent variable. Wald tests assessed statistical
significance of differences between growth rates in two
mouse groups.
Results
RSV-induced oncolysis of LNCaP and RM1 cells
Figure 1 show that similar to PC-3 androgen-indepen-
dent prostate cancer cells RSV induces apoptosis due to
its oncolytic activity against androgen-sensitive LNCaP
prostate cancer cells and RM1 murine prostate cancer
cells. Apoptosis was minimal for RWPE-1 non-malig-
nant prostate epithelial cells. Compared to RWPE-1,
RSV titer was drastically enhanced in LNCaP and RM1
cells (Figure 1a). This led to increased cytopathicity (evi-
dent from cell rounding and loss of normal cellular
morphology) (Figure 1b) and reduced cell viability
(Figure 1c). Reduced cell viability was due to increased
apoptosis of RSV infected LNCaP and RM1 cells (Figure
1d). Cancer cell-selective apoptosis relative to non-
tumorigenic RWPE-1 prostate cells indicated that RSV
imparts oncolytic activity on LNCaP and RM1 cells.
RSV-induced oncolysis of androgen-dependent and
androgen-independent prostate cancer cells in the
absence and presence of androgen
To assess the role of androgen in the RSV effect on
LNCaP (androgen-dependent) and C4-2B (androgen-
independent, derived from the parental LNCaP) cells,
the cells were grown in androgen-depleted (charcoal
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R1881a (1 nM) was added to the media for overnight
before mock infection or infection with RSV was per-
formed. RSV replicated efficiently in vehicle-treated and
R1881 (1 nM)-treated LNCaP and C4-2B prostate can-
cer cells (Figure 2a, d). The RSV titer was higher in cells
with androgen treatment compared to vehicle treatment.
Cell morphology (Figure 2b, e) revealed that RSV caused
oncolysis of LNCaP and C4-2B cells in an androgen-
independent manner.
The presence of androgen caused more extensive
apoptosis of LNCaP cells (80% apoptosis) than in the
a b s e n c eo ft h eh o r m o n e( 5 0 %a p o p t o s i s )( F i g u r e2 c ) .
Given the androgen dependence of these cells, the much
higher apoptosis of mock-infected cells in the absence of
androgen is expected.
Figure 1 Oncolytic activity of RSV. (a) RSV infection of RWPE-1, LNCaP and RM1 cells were measured by plaque assay at 36 h post-infection.
Plaque assay values expressed as pfu/ml represent mean ± standard deviation for three independent determinations. Standard deviations are
shown by the error bars. (b) Morphology of mock-infected or RSV-infected cells at the indicated post-infection time periods. (c) MTT cell viability
assay of cells infected with RSV for 36 h. MTT assay values are mean ± standard deviation of 6 wells and triplicate experiments. Uninfected (-)
cells indicate 100% cell viability. (d) RSV mediated apoptosis at 24 h post-infection. % Apoptosis represents the % of cells that are undergoing
apoptosis (i.e. positive for annexin V staining). The values represent mean ± SD for three determinations.
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Page 4 of 18Figure 2 Oncolytic activity of RSV against androgen-dependent and androgen-independent prostate cancer cells in the absence and
presence of androgen. (a) RSV infection of LNCaP cells (in the presence or absence of androgen) were measured by plaque assay as described
in Figure. 1a. Standard deviations are shown by the error bars. (b) Morphology of mock-infected or RSV-infected LNCaP cells (in the presence or
absence of androgen). (c) Apoptosis of mock-infected (- RSV) and RSV-infected (+ RSV) LNCaP cells (in the presence or absence of androgen).
Apoptosis assay was performed as described in Figure 1 d. The figure shows the percentage of cells undergoing apoptosis. Standard deviations
are shown by the error bars. (d) RSV infection of C4-2B cells (in the presence or absence of androgen) were measured by plaque assay as
described in Figure. 1a. Standard deviations are shown by the error bars. (e) Morphology of mock-infected or RSV-infected C4-2B cells (in the
presence or absence of androgen).
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apoptosis
Intratumoral administration of RSV to the subcuta-
neously produced LNCaP xenograft tumors markedly
reduced tumor mass over a three week period, while
medium-injected tumors (carrier control) continued to
increase in size over time (Figure 3a). Photomicro-
graphic documentation of tumor regression in a
Figure 3 Androgen-sensitive LNCaP xenograft prostate tumor growth in nude mice following intratumoral injection of RSV.T u m o r s
were produced by subcutaneous injections of LNCaP cells at sites below the ear. (a) Tumor growth kinetics in mice. Intratumoral injections were
given at 2 days apart. Tumor volume of each mouse was normalized against its tumor volume at day 1 (starting point) set as 100%. Tumor
volumes (normalized) measured on each injection day are shown in the plot. Each treatment group consisted of four representative animals (n =
4) and data represent normalized mean tumor volume trajectories over time. Error bars represent the SE of the mean at each time point. (b)
Progressively regressed tumor mass after intratumoral injection of RSV. Tumor growth corresponding to injections of RSV or Medium was
followed. Day 1 represents the initial injection of RSV or Medium. The Inserts display corresponding tumors extracted at day-22 before sacrifice.
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ing nude mice receiving medium injection showed dras-
tic reduction in body weight. This is in contrast to the
steady body-weight increase in mice that received RSV
into tumors (Figure 4a). We speculate that the
decreased body weight (cancer cachexia) is due to the
catabolic action of the proteolysis-inducing factor (PIF)
on skeletal muscle and possibly, to some extent, also
due to the catabolic action of TNF-a (cachectin) on the
adipose tissue and skeletal muscle [16]. Thus, the anti-
tumor activity of RSV helps relieve tumor-associated
pathophysiological ailments.
Real-time bioluminescence imaging in live mice (using
Xenogen IVIS imaging system) also showed drastic
tumor regression by RSV (Figure 4b). The tumor regres-
sion was directly due to lytic viral replication in tumor
cells, since high RSV titer was detected in the homoge-
nate of the LNCaP xenograft tumor tissue that was har-
vested 3 days after a single RSV injection via I.T (Figure
4c).
Furthermore, the oncolytic effect of RSV is not com-
promised in the immune-competent syngeneic host,
since RSV significantly inhibited growth of RM1 murine
prostate cancer cell tumors generated in C57BL/6J mice
(Figure 5a). We observed that RSV specifically targeted
and localized to LNCaP- and RM1-derived prostate
tumors since viral gene specific mRNA expression was
detected in tumor lysates, but not in lysates of various
organs (lungs, kidney, liver, spleen) of infected animals
(data not shown). Similar tumor-specific RSV targeting
was noted previously in mice harboring PC-3 derived
xenograft tumor [7].
Intratumoral RSV injection significantly enhanced
apoptosis of tumor cells (shown by in situ TUNEL
assay) for LNCaP (Figure 5b) and RM1 (Figure 5c)
derived tumors compared to control tumors. This con-
curs with our in vitro data of RSV-induced apoptosis in
LNCaP and RM1 cells (Figure 1d).
Sustained tumor remission after RSV administration and
subdued immune response to RSV challenge
The therapeutic potential of RSV was further evident
from its long-term anti-tumorogenic impact. Xenograft
prostate tumors (from luciferase expressing LNCaP-Luc-
2 cells), subjected to four RSV injections (at 2 days
apart), resulted in tumor regression and the tumor failed
to reappear even at 44 days after the final RSV injection
(Figure 6a). The long-term tumor remission following
RSV treatment underscores the feasibility of developing
RSV as an efficient anti-cancer agent.
Immune responses directed against viruses pose a
major hurdle in developing efficient oncolyitc viruses
with potent anti-cancer property. In that regard,
immune response against RSV was minimal, since RSV
failed to induce robust immunity following systemic (via
intraperitonial or i.p route) infection of normal,
immuno-competent C57BL/6J mice that did not host
xenograft tumors. Very low levels of Th1 (IFN-g)a n d
Th2 (IL-10) cytokines (0.25-0.90 pg/ml of IL-10 and
IFN-g respectively, in the spleen homogenate) in
infected animals were indicative of weak immune
response following systemic RSV infection (Figure 6b).
Systemic challenge with various foreign agents (bacteria,
virus etc) typically produces 100-3500 pg/ml of IL-10
and IFN-g in the spleen [17-19].
We also examined whether RSV triggered immune
response in the tumor micro-environment. LNCaP
xenograft tumors were injected with RSV (two injections
via I.T route; 2-day apart) and tumor lysate (collected 2
d after the last injection) was analyzed for the Th1 and
Th2 cytokine levels. The almost non-detectable immune
mediators (Figure 6b) suggest that tumor regression is
not due to host adaptive immunity and self-elimination.
These results along with our data showing lytic RSV
replication in the tumors (Figure 4c) suggest that tumor
regression occurred mostly due to a direct RSV-
mediated apoptosis of tumor cells.
Tumor pathology
After administering 7 injections of RSV or medium
intra-tumorally (injected every other day), tumors were
examined for pathological status. The most prominent
change for RSV-injected tumors, compared to medium-
injected tumors, was complete necrosis with no histolo-
gically discernable tumor cells (Figure 7). RSV infected
tumors showed markedly reduced size containing a cen-
tral necrotic core surrounded by a fibrous pyogranula-
matous capsule. The normal inflammatory process led
to significant healing, as revealed by replacement of the
tumor mass by non-malignant tissue (compare Figure
7d with Figure 7a). Histological evaluations of RSV-
injected versus medium-injected tumors (3 tumor speci-
mens in each group) are presented in Table 1. Differ-
ences between the control and experimental group are
easily discernable. Differences were most prominent in
t h ed e g r e eo fi n v a s i v e n e s s ,( 4 ,4a n d5v s .0 ,0a n d0 ) ,
mitotic figures per high power field (2, 11 and 22 vs. 0,
0a n d0 ) ,n e c r o s i s( 2 ,1a n d2v s .5 ,5a n d5 ) ,c o m p r e s -
sion of adjacent tissue (2, 1 and 2 vs. 0, 0 and 0), miner-
alization (0, 0 and 0) vs. 4, 3 and 3). Differences for
several additional criteria (edema, congestion, hemor-
rhage, and hemosiderin deposition) were not significant.
Loss of IFN-regulated antiviral defense in LNCaP cells
A critical antiviral role of type-I IFN cytokines in
restricting infection from RSV and various other viruses
such as measles and vesicular stomatitis virus has been
demonstrated [10,20-23]. Therefore, we investigated
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Page 7 of 18Figure 4 in vivo oncolytic activity of RSV against androgen-sensitive xenograft prostate tumor. (a) Body weight of tumor bearing mice
measured over 14 day following intratumoral administration of RSV or Medium at 2-day intervals. The body weight data represent the
normalized mean body weight trajectories over time. Body weight of each mouse was normalized against its body weight at day 1, which was
set as 100%. Error bars represent the SE of the mean at each time point. (b) Real-time bioluminescence imaging of xenograft tumors (generated
using luciferase expressing LNCaP-Luc-2 cells) in live animal following RSV or medium (control) injections (I.T). Time interval for each injection =
2 days. Whole-body imaging was done with Xenogen IVIS system. (c) LNCaP xenograft tumor was injected either with medium (control) or RSV
(1 × 10
5 pfu) via I.T. After 3 d post-injection, the tumor was surgically removed and RSV titer in the tumor homogenate was determined by
plaque assay.
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Page 8 of 18Figure 5 Growth of prostate tumors in immune-competent C57BL/6J mice and RSV-mediated apoptosis of prostate tumors in situ. (a)
RM1 murine prostate cancer cell tumors, grown subcutaneously in C57BL/6J mice, were injected with RSV or medium (intratumoral). Each
treatment group had four representative animals (n = 4) and data represent the normalized mean tumor volume trajectories over time. Tumor
volume of each mouse was normalized against its tumor volume at day 1 of injection, which was set as 100%. Error bars represent SE of the
mean. (b, c) TUNEL assay with prostate tumors derived from LNCaP (a) or RM1 (b) cells (at 100× magnifications). Tumors, injected with RSV or
Medium (control), were excised, processed and tumor sections were analyzed by TUNEL assay. RM1 tumors were derived 12 h after two RSV
injections (2 d apart) via intratumoral route. In contrast, LNCaP tumors were derived 12 h after three RSV injections (2 d apart) via intratumoral
route.
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ism would account for differential oncolytic activity in
LNCaP versus RWPE-1 cells.
Deregulation of IFN-mediated antiviral response could
occur due to either insufficient IFN production from
cancer cells, or a dysfunctional IFN-activated JAK/STAT
antiviral pathway. RSV-infected LNCaP cells produced
high levels of IFN - even more than RWPE-1 cells (Fig-
ure 8a). However, the antiviral activity of IFN (as mea-
sured from the viral titer of the RSV-infected cells) was
at least 100-fold higher in the case of RWPE-1 and PC-
3 compared to LNCaP cells (Figure 8b). For these
experiments (Figure 8b), cells were pre-treated with IFN
for 16 h, followed by RSV infection in the continued
presence of IFN. The viral titer was measured by per-
forming plaque assay of medium supernatants.
Representative plaque assay shows that IFN treatment
caused drastic reduction of RSV infectivity in RWPE-1
(12 h and 24 h post-infection), while failing to signifi-
cantly inhibit RSV infectivity/replication in LNCaP cells
a t1 2ha n d2 4hp o s t - i n f e c t i o n( F i g u r e8 c ) .I nc o n t r a s t
to LNCaP cells, PC-3 cells were protected against RSV
to the antiviral action of IFN, since IFN treatment of
PC-3 cells drastically inhibited virus replication (Figure
8d). In the absence of protection from IFN, RSV has
selective growth advantage in LNCaP cells over RWPE-1
cells and PC-3 cells. Indeed, the IFN neutralizing anti-
body, which inhibited IFN-a/b mediated antiviral activ-
ity in RWPE-1 cells, caused significant elevation of the
RSV titer in RWPE-1 cells (by approximately 15 fold),
representing enhancement of viral infectivity by 750%
(Figure 9a). A representative result from plaque assay of
Figure 6 Sustained tumor remission after RSV administration and subdued immune response to RSV challenge. (a) RSV was
administered (via I. T - four injections at 2-day intervals) to xenograft tumor (generated from luciferase expressing LNCaP-Luc2 cells). Following 4
injections, the mouse was observed everyday for a period of 44 days for tumor recurrence. Real-time bioluminescence imaging of xenograft
tumors in the live animal was performed with Xenogen IVIS system. (b) Levels of interferon-g (IFNg) & interleukin-10 (IL-10) in spleen
homogenate of normal, C57BL/6J mice (non-tumor bearing) infected with RSV (4 injections of RSV, 2 days apart -10
6 pfu/mouse via i.p.) were
measured (by ELISA) at the day-14 following last injection. Cytokines were also measured in xenograft prostate tumor (subcutaneous tumor
generated using LNCaP cells) 48 hr after RSV injections via I.T. The representative results are from duplicate experiments with similar values.
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either control antibody or IFN-neutralizing antibody
shows elevated viral titer in cells devoid of IFN response
(Figure 9b). Results from Figure 9 demonstrate that IFN
plays an important role in limiting RSV infection in
RWPE-1 and PC-3 cells, whereas lack of this restriction
in LNCaP cells associated with excessive viral replication
and oncolysis.
We had reported earlier [7] that PC-3 cells are suscep-
tible to RSV-induced apoptosis despite an intact IFN-
responsive antiviral response (Figure 8b). This is due to a
defect in the NF-B-mediated antiviral response, which
was compromised within 6-12 h post-infection (Figure
10c). However, RSV-infected LNCaP and RWPE-1 cells
were not impaired for NF-B activation (Figures 10a, b).
Lack of IFN-regulated STAT-1 activation in RSV-infected
LNCaP cells
Following engagement with the cognate IFN-receptor,
IFN-a/b stimulates a signaling cascade (JAK/STAT
Figure 7 Histopathology of LNCaP xenograft prostate tumors. (a) Photograph of tumor (at 20× magnification), injected with medium shows
an irregular expansible growth and compression (marked as C) of adjacent normal tissue, revascularization (marked as NV) and vascular
metastasis (marked as M). (b) 100× magnification of the upper square in panel-a (solid-line boundary for the demarcated box), showing
prominent vascular metastasis (M). (c) 400× magnification of the lower dashed square (demarcated by the broken-line boundary) in panel-a,
showing a typical mitotic figure (see arrow). (d) Photograph (at 20X) of RSV-injected tumor. Tumor size is markedly reduced and complete
necrosis of the neoplastic cells with minimal fibrovascular encapsulation and pyogranulamatous inflammation is evident. Marked necrosis at the
center of the tumor is readily apparent. (e) 100× magnification and (f) 400× magnification of the solid-line square in panel-d, highlighting
minimal fibrovascular encapsulation, FV (panel-e) and complete tumor necrosis, TN (panel-f). NT: normal tissue. ND: non-tumor debris.
Echchgadda et al. BMC Cancer 2011, 11:43
http://www.biomedcentral.com/1471-2407/11/43
Page 11 of 18pathway) that culminates in activation of the transcrip-
tion factors STAT-1 and STAT-2 (STAT-1/2), which
translocates to the nucleus to transactivate antiviral
genes [24]. Although LNCaP cells secreted high levels of
IFN (Figure 8a), unlike RWPE-1 and PC-3 cells, RSV-
infected LNCaP cells did not activate STAT-1, revealed
f r o mt h el a c ko fS T A T - 1b i n d i n gt ot h ec o g n a t eD N A
element in LNCaP cells (Figure 11a) in contrast to
RWPE-1 (Figure 11a) and PC-3 (Figure 11b) cells, which
showed robust STAT-1 activation. EMSA complexes in
RWPE-1 and PC-3 cells are shown by the arrow, and
specificity of the EMSA is shown by the loss of STAT-
1-specific EMSA complex in competition assay (Figure
11a, b).
We conclude that inability of LNCaP cells to activate
STAT-1 in response to RSV infection is due to a glob-
ally dysfunctioning IFN pathway, since IFN treatment
did not activate STAT-1 in LNCaP cells (Figure 11c).
Discussion
Our study has been the first to demonstrate RSV is an
oncolytic virus, and this oncolytic activity is functional
in vivo both in immune-deficient nude mice and in an
immune-competent host environment, since RSV inhib-
ited prostate tumor growth in syngeneic C57BL/6J mice.
RSV infectivity and the virus-induced apoptotic index in
vitro were much higher in androgen-dependent LNCaP
cells compared to non-tumorigenic RWPE-1 prostate
cells. Aberrant type I interferon (IFN)-dependent anti-
viral defense response [10], which culminated in
impaired activation of the STAT-1 transcription factor
(STAT-1 is required for expression of IFN-dependent
antiviral genes), associated with the high RSV burden in
infected LNCaP cells. We conclude that blockade in
STAT-1 activation, leading to inhibition in the expres-
sion of critical IFN-dependent antiviral genes, accounts
for excessive RSV replication leading to apoptosis of
LNCaP cells. This is unlike PC-3 androgen-independent
prostate cancer cells for which RSV-induced oncolysis
was associated with failure in a sustained NF-Ba c t i v a -
tion, which would cause failure in the induction of NF-
B dependent antiviral genes.
Using IFN-neutralizing antibody, we also provide the
first direct evidence (Figure 9) that protection of non-
malignant epithelial cells against virus-induced oncolysis
is due to IFN-mediated antiviral defense response. Our
results further revealed that the oncolytic function of
RSV may remain active even when the IFN-regulated
antiviral pathway is functional, provided a second
defense arm involving NF-B signaling is deregulated.
Innate immunity is the first line of defense mounted
by the host to combat virus infection before an orche-
strated adaptive immune response is launched [10,20].
IFN-mediated activation of the JAK/STAT antiviral
pathway is recognized as a major antiviral innate
immune defense mechanism [24]. In this regard, we
have recently demonstrated that RSV-infected lung
epithelial cells and immune cells (e.g. macrophages) uti-
lize Nod2 protein as a molecular sensor to induce pro-
duction of IFN-a/b from infected cells after interacting
with viral single-stranded RNA genome and subse-
quently triggering innate antiviral response [25]. IFN-a/
b, which are potent antiviral cytokines produced in
infected cells, bind to cognate cell surface receptors on
uninfected cells (via autocrine/paracrine action) to
induce the JAK/STAT antiviral pathway; which helps
promote nuclear translocation and activation of the
transcription factors STAT-1 and STAT-2 that in turn
activate antiviral genes [24]. We also reported that an
IFN-independent innate defense mechanism involving
TNF-a -induced activation of NF-B can restrict virus
replication in infected cells due to induction of antiviral
genes [15,26]. These two antiviral pathways mediated by
IFN (via the JAK/STAT pathway) and TNF-a (via the
NF-B pathway) are activated in infected cells either
individually or together to coordinate the transcriptional
induction of the antiviral gene network.
A large number of cancer cells are deficient in the IFN
signaling cascade [27,28], making many types of cancer
cells susceptible to apoptosis by oncolytic viruses. In the
context of prostate cancer, our results suggest that both
androgen-dependent prostate cancer cells (such as
LNCaP cells) and androgen-independent prostate cancer
cells (such as PC-3 and RM1 cells) are susceptible to
RSV-induced oncolysis. We show that, while IFN pro-
duction from infected LNCaP cells was normal, IFN
failed to activate STAT-1 in LNCaP cells. In fact, it was
reported earlier that LNCaP cells fail to express JAK1
[29]. On the other hand, RSV infection and IFN treat-
ment of non-tumorogenic RWPE-1 cells and PC-3 cells
was associated with robust STAT-1 activation and
Table 1 Histological evaluation of Medium- and RSV-
injected tumors
Slide
ID
Injection Invasion m/
hpf
Necrosis Compression Min. NV
1 Medium 4 2 2 2 0 5
2 Medium 4 11 1 1 0 3
3 Medium 5 22 2 2 0 2
4 RSV 0 0 5 0 4 2
5 RSV 0 0 5 0 3 2
6 RSV 0 0 5 0 3 0
Histological evaluations of RSV-injected versus medium-injected tumors (3
tumor specimens in each group) are presented. Tumor sections were stained
with hematoxylin and eosin. For each tumor sample, pathologic changes were
graded by a blinded, board certified veterinary pathologist (GBH) as 0 =
normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = moderately severe, 5 =
severe. Grading criteria were based on invasion of adjacent normal tissue,
necrosis, mitotic figures per 20X high power field (m/hpf*), compression of
the surrounding tissue, mineralization (min
§) and neovascularization (NV
II).
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Page 12 of 18Figure 8 Interferon response of prostate cancer cells. (a) IFN-b production from mock-infected and RSV-infected RWPE-1 and LNCaP cells
was measured at 12 h and 24 h post-infection. Amount of IFN-b deduced from the ELISA assay was expressed as pg/ml and each value
represents mean ± standard deviation for three determinations. (b) RSV infectivity in untreated (UT) and IFN pre-treated cells was measured by
plaque assay at 24 h post-infection. The values are fold reductions in the RSV titer following IFN pre-treatment compared to untreated cells.
Mean ± standard deviation for three determinations are shown. (c) Plaque assay showing RSV infectivity in untreated (UT) and IFN pre-treated
RWPE-1 and LNCaP cells. Culture supernatant collected from RSV infected cells were added to CV-1 cells at various dilutions (1 × 10
4 -1×1 0
6
dilutions). (d) Plaque assay showing RSV infectivity in untreated (UT) and IFN pre-treated RWPE-1 and PC-3 cells at 24 h post-infection. Culture
supernatant collected from RSV infected cells was added to CV-1 cells at various dilutions (1 × 10
5 and 1 × 10
8 dilutions). For figures (c) and (d)
the plaques were observed on methyl-cellulose after crystal-violet staining. Please note that figures (c) and (d) are two separate experiments.
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Page 13 of 18protection against RSV-induced apoptosis. We also
show that while PC-3 cells respond to IFN and induce
DNA-binding activity of STAT-1 (in agreement with
previous reports that IFN-treated PC-3 cells are acti-
vated for antiviral signaling; [30,31]), impaired NF-B
activation is associated with apoptosis in RSV-infected
PC-3 cells. LNCaP cells, on the other hand, were com-
petent to activate NF-B in response to RSV infection.
We speculate that androgen dependence and/or the
androgen receptor expression status of prostate cancer
cells may influence RSV-mediated modulation of the
innate antiviral apparatus (NF-B activation vs. IFN-
Figure 9 Interferon response is essential for limiting RSV infection in prostate cells. (a) RSV infection of RWPE-1 in the absence (untreated,
UT) or in the presence of either control (Con Ab) or IFN neutralizing (IFN Ab) antibody. Infection was measured by plaque assay at 36 h post-
infection. Plaque assay values expressed as pfu/ml represent mean ± standard deviation for three independent determinations. Standard
deviations are shown by error bars. (b) Plaque assay showing RSV infectivity in Con Ab or IFN Ab treated cells. Culture supernatant from RSV
infected RWPE-1 cells (+/- Con Ab or IFN Ab) was added to CV-1 cells at a dilution of 1 × 10
6. Plaques were observed on methyl-cellulose after
crystal-violet staining.
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Page 14 of 18mediated JAK/STAT activation). Our results (Figures 8,
9, 10, 11) [7] lead us to conclude that deregulation of
the IFN pathway in androgen-sensitive LNCaP prostate
cancer cells accounts for loss of STAT-1 activation (and
non-expression of antiviral factors), higher RSV replica-
tion, induction of apoptosis and reduced cell viability,
whereas deregulation of the NF-B-dependent antiviral
defense in androgen-independent PC-3 prostate cancer
cells accounts for susceptibility of these cells to RSV-
induced apoptosis.
Advanced-stage cancer cells, which continue to
express the androgen receptor in a majority of tumor
specimens, are resistant to apoptosis from androgen
ablation or from the cytotoxicity induced by
chemotherapeutic agents. Development of treatment
protocols that would promote prostate cancer cell apop-
tosis and prevent cancer cell progression to androgen
independence has remained a major challenge in pros-
tate cancer therapy. To this end, it is tempting to specu-
late that complete ablation of prostate cancer cells at an
early stage, when the cells are still androgen-sensitive, is
likely to prevent clonal emergence of androgen-indepen-
dent prostate cancer cells. The anti-tumor, oncolytic
activity of RSV against androgen receptor-negative pros-
tate tumors has additional clinical significance, since
reduced or non-detectable androgen receptor expression
has been observed in a small percent of metastatic neo-
plastic foci at distant organ sites from castrate resistant
Figure 10 NF-B activation in RSV infected prostate cancer cells. NF-B specific EMSA of nuclear extracts prepared from mock-infected and
RSV-infected LNCaP (a) RWPE-1 (b) and PC-3 (c) cells. Duration of infection (in hours) with RSV is indicated. The NF-B/DNA EMSA complex is
indicated with arrowheads. Competition of the EMSA complex with the cold NF-B duplex oligonucleotide, but not with cold STAT1/2 oligo
duplex in panel (a) ensures the specific nature of the EMSA complex.
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Page 15 of 18prostate cancer patients [32,33]. The observation that
RSV-induced oncolysis of prostate tumors can occur in
immune-competent C57BL/6J mice has obvious clinical
significance. It is important to mention that systemic
d e l i v e r yo fR S Vr e p r e s e n tac l i n i c a l l yf e a s i b l er o u t ef o r
therapy. In that regard, we have previously demon-
strated that intraperitoneal (i.p.) injections of RSV are
effective in causing regression of PC-3 xenograft tumors
[ 7 ]w h i c ha r em o r ea g g r e s s i v et h a nL N C a Px e n o g r a f t
tumors with regard to tumor growth. Thus, studies are
Figure 11 Impaired IFNa- and RSV-mediated STAT-1 activation in LNCaP cells. STAT-1-specific EMSA of nuclear extracts prepared from
mock-infected and RSV-infected LNCaP and RWPE-1 cells (a) PC-3 cells (b). The STAT-1/DNA EMSA complex is indicated with arrowheads. (c)
STAT-specific EMSA of nuclear extracts prepared from cells treated with (+) or without (-) IFNa for 4 hours. Asterisks represent STAT-1/DNA
complex. NS: non specific band.
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Page 16 of 18underway to examine oncolytic efficacy of RSV against
LNCaP tumors following systemic administration. The
results from our study suggest that RSV-based therapy
has the potential to be a viable strategy for prostate can-
cer treatment.
Conclusions
In summary, our study demonstrated the oncolytic activity
of RSV promotes selective apoptosis of androgen-sensitive
and androgen-refractory prostate cancer cells by exploiting
the deficiency in the antiviral signaling propagated by either
the IFN-mediated JAK/STAT activation or NF-B activa-
tion in virus infected cells. The host immune response did
not interfere with the oncolytic activity of RSV. On the
basis of these results we suggest that the oncolytic property
of RSV may be useful in the development of virotherapy for
noncurative, metastatic prostate cancer.
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